{"entity":{"id":"rondo-therapeutics","kind":"company","name":"Rondo Therapeutics","aka":[],"tldr":"Rondo Therapeutics makes two-armed antibodies that grab a tumour protein with one arm and give T cells an extra activation signal with the other, so the immune system attacks solid tumours. Its first drug, RNDO-564, is in an early trial for bladder cancer and other tumours that carry Nectin-4.","summary":"Rondo Therapeutics, at 25801 Industrial Boulevard, Hayward, California, was co-founded by chief executive Shelley Force Aldred and chief scientific officer Nathan Trinklein and develops immune-cell engaging bispecific antibodies for solid tumours using an NGS-based antibody discovery platform with a fixed light-chain format. The lead candidate RNDO-564 is a CD28 x Nectin-4 bispecific, tested alone and with pembrolizumab in a phase 1/1b study in bladder cancer and other Nectin-4 associated solid tumours, including non-small cell lung, cervical, head and neck and triple-negative breast cancers. Earlier programmes pair CD3 and CD28 arms with undisclosed targets for ovarian, endometrial and renal cancers, and the company announced a collaboration with Lilly on CD28 bispecific antibodies in December 2024. Its first registered cancer trial, NCT07218003, was posted on ClinicalTrials.gov in October 2025. In March 2022 it closed a USD 67 million Series A co-led by Red Tree Venture Capital and Canaan Partners with Johnson & Johnson Innovation (JJDC), Novo Holdings and SV Health Investors.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.rondotx.com/"},{"label":"Collaboration with Lilly on CD28 bispecific antibodies, December 2024","url":"https://www.businesswire.com/news/home/20241204127623/en/Rondo-Therapeutics-Announces-Collaboration-with-Lilly-to-Develop-Novel-CD28-Bispecific-Antibodies-for-Solid-Tumors"},{"label":"ClinicalTrials.gov: phase 1/1b trial of RNDO-564 alone or with pembrolizumab (NCT07218003)","url":"https://clinicaltrials.gov/study/NCT07218003"}],"tags":[],"related":[],"cancers":["urothelial","head-and-neck","nsclc","cervical","tnbc"],"sections":["immunotherapy"],"technologies":["bispecific-antibody"],"targets":["cd28","nectin4"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07218003"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website.","The Lilly collaboration is listed from its headline on the company website; terms were not read."," CD28 bispecifics are costimulatory rather than CD3 T-cell engagers, so the record links the bispecific antibody record only.","Company website and the 2022 Series A release read on 29 October 2026."],"hq":"Hayward, CA","country":"US","companyType":"biotech","website":"https://www.rondotx.com/","stage":"growth","investors":["jjdc","novo-holdings","sv-health-investors"],"funding":[{"round":"Series A","year":2022,"amountUsd":67000000,"source":"https://www.prnewswire.com/news-releases/rondo-therapeutics-closes-67-million-series-a-financing-to-advance-next-generation-immuno-oncology-platform-for-solid-tumors-301493486.html","note":"Co-led by Red Tree Venture Capital and Canaan Partners."}]},"route":"/companies/rondo-therapeutics/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"}],"target":[{"id":"cd28","kind":"target","name":"CD28","route":"/targets/cd28/"},{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"}],"trial":[{"id":"nct07218003","kind":"trial","name":"RNDO-564 alone or with pembrolizumab","route":"/trials/nct07218003/"}],"company":[{"id":"jjdc","kind":"company","name":"Johnson & Johnson Innovation - JJDC","route":"/companies/jjdc/"},{"id":"novo-holdings","kind":"company","name":"Novo Holdings","route":"/companies/novo-holdings/"},{"id":"sv-health-investors","kind":"company","name":"SV Health Investors","route":"/companies/sv-health-investors/"}]}}